ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1904 • 2014 ACR/ARHP Annual Meeting

    Rheumatoid Factor Isotype Testing to Identify Individuals in the Preclinical Period of Rheumatoid Arthritis

    M. Kristen Demoruelle1, Anthony Kahr1, Mark C. Parish1, Marie L. Feser1, Ryan W. Gan2, Jason R. Kolfenbach1, William R. Gilliland3, Jess D. Edison3, Michael H. Weisman4, James R. O'Dell5, Ted R. Mikuls6, Richard M. Keating7, Peter K. Gregersen8, Jane H. Buckner9, Jill M. Norris2, V. Michael Holers10 and Kevin D. Deane1, 1Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2Epidemiology, Colorado School of Public Health, Aurora, CO, 3Walter Reed National Military Medical Center, Bethesda, MD, 4Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 5Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 6Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 7Division of Rheumatology, Scripps Clinic, La Jolla, CA, 8Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, 9Benaroya Research Institute at Virginia Mason, Seattle, WA, 10Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Rheumatoid arthritis (RA)-related autoantibody (Ab) testing for Abs to cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) are used in the clinical diagnosis of…
  • Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting

    Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses

    Dirkjan van Schaardenburg1, Mairead Murphy2, Yuan Gui2, Samina Turk3, Walter P. Maksymowych4 and Anthony Marotta5, 1Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, 2Augurex Life Sciences Corp., North Vancouver, BC, Canada, 3Reade, Amsterdam, Netherlands, 4Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, 51423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada

    Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
  • Abstract Number: 1902 • 2014 ACR/ARHP Annual Meeting

    Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity

    Michelle Ormseth1, Cecilia P. Chung2, Joseph F. Solus3, Annette M. Oeser3, Margery A. Connelly4, Jim Otvos4 and C Michael Stein3, 1Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, 2Medicine, Vanderbilt University, Nashville, TN, 3Vanderbilt University, Nashville, TN, 4LipoScience, Inc., Raleigh, NC

    Background/Purpose GlycA is a novel inflammatory biomarker measured from the nuclear magnetic resonance (NMR) spectra obtained for lipoprotein particle analysis. It represents a distinct peak…
  • Abstract Number: 1901 • 2014 ACR/ARHP Annual Meeting

    Interferon-γ (IFNγ) in Macrophage Activation Syndrome (MAS) Associated with Systemic Juvenile Idiopathic Arthritis (sJIA). High Levels in Patients and a Role in a Murine MAS Model

    Claudia Bracaglia1, Ivan Caiello1, Kathy De Graaf2, Giovanni D'Ario2, Florence Guilhot2, Walter Ferlin2, Lidia Meli1, Giusi Prencipe1, Sergio Davì3, Grant Schulert4, Angelo Ravelli5, Alexei Grom6, Cristina De Min2 and Fabrizio De Benedetti Sr.1, 1Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 3Pediatria II, Istituto Giannina Gaslini, Genova, Italy, 4Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Istituto Giannina Gaslini and University of Genova, Genova, Italy, 6Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: IFNγ is the pivotal mediator in murine models of primary HLH. Given the similarities between primary and secondary (sHLH), including MAS, we analyzed IFNγ…
  • Abstract Number: 1900 • 2014 ACR/ARHP Annual Meeting

    HLA-DRB1*1101, Regulatory Variants of the MHC, and a Regulatory Region Near an Intergenic Long Noncoding RNA on Chromosome 1 Are Risk Factors for Systemic Juvenile Idiopathic Arthritis

    Michael J. Ombrello1, Elaine F. Remmers2, Ioanna Tachmazidou3, Alexei Grom4, Dirk Föll5, Alberto Martini6, Marco Gattorno7, Seza Ozen8, Sampath Prahalad9,10, Andrew S. Zeft11, John F. Bohnsack12, Norman T. Ilowite13, Jane L. Park14, Elizabeth D. Mellins15, Ricardo A. G. Russo16, Claudio A. Len17, Sheila K. Feitosa de Oliveira18, Rae SM Yeung19, Lucy R. Wedderburn20,21, Jordi Anton22, Tobias Schwarz23, Buhm Han24, Richard H. Duerr25, Jean-Paul Achkar26, M. Ilyas Kamboh27, Kenneth M. Kaufman28, Leah C. Kottyan28, Dalila Pinto29, Stephen Scherer30, Marta E. Alarcón-Riquelme31, Elisa Docampo Martinez32, Xavier Estivill33, Ahmet Gul34, Colleen Satorius35, Paul I.W. de Bakker36,37,38, Soumya Raychaudhuri37,39,40, Carl D. Langefeld41, Susan D. Thompson42, Eleftheria Zeggini3, Wendy Thomson43, Daniel L. Kastner44, Patricia Woo45 and International Childhood Arthritis Genetics (INCHARGE) Consortium, 1Translational Genetics and Genomics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 4Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, 6University of Genova, Genova, Italy, 7Pediatric Rheumatology, Instituto Giannina Gaslini, Genoa, Italy, 8Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 9Emory University School of Medicine, Atlanta, GA, 10Children's Healthcare of Atlanta, Atlanta, GA, 11Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, 12Pediatriacs, University of Utah, Salt Lake City, UT, 13Pediatrics, Albert Einstein College of Medicine, Bronx, NY, 14Pediatric Rheumatology, Stanford University Medical Center, Stanford, CA, 15Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, 16Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 17Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil, 18Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 19Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 20University College London (UCL) Institute of Child Health, London, United Kingdom, 21Great Ormond Street Hospital, London, United Kingdom, 22Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, 23Pediatric rheumathology and osteology, University of Wuerzburg, Wuerzburg, Germany, 24Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, 25Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, 26Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, 27Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, 28Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 29Genetics and Genomi Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 30The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada, 31Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 32Unit of Animal Genomics, GIGA-Université de Liège, LIege, Belgium, 33Genetic Causes of Disease Laboratory, Center for Genomic Regulation, Barcelona, Spain, 34Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 35National Human Genome Research Institute, Bethesda, MD, 36Brighan and Women's Hospital, Harvard Medical School, Boston, MA, 37Broad Institute of MIT and Harvard, Cambridge, MA, 38University Medical Center Utrecht, Utrecht, Netherlands, 39Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 40Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 41Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 42Division and Center for Autoimmune Disease Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 43Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 44Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, 45Paediatric Rheumatology Unit, University College London, London, United Kingdom

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory disease of unknown etiology.  We utilized a genomic approach to interrogate the molecular pathogenesis of…
  • Abstract Number: 1899 • 2014 ACR/ARHP Annual Meeting

    Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis

    Julia Rood1, Portia Kreiger2, Erietta Stelekati1, E. John Wherry1 and Edward M. Behrens3, 1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Pathology, Alfred I. duPont Hospital for Children, Wilmington, DE, 3Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose Cytokine storm syndromes, such as macrophage activation syndrome and familial hemophagocytic lymphohistiocytosis (FHL), represent important causes of mortality in pediatric rheumatology. Studies of a…
  • Abstract Number: 1898 • 2014 ACR/ARHP Annual Meeting

    Identification of “autoinflammatory interferonopathies”?   a New Class of Autoinflammatory Conditions?

    Adriana Almeida de Jesus1, Zuoming Deng2, Stephen Brooks3, Yin Liu4, Hanna Kim4, Gina A. Montealegre Sanchez4, Dawn C. Chapelle4, Yan Huang4, Philip Hashkes5, Gulnara Nasrullayeva6, Maria Teresa Terreri7, Bita Arabshahi8, Marilynn G. Punaro9, Lakshmi N. Moorthy10, Adam Reinhardt11, Clovis A. Silva12, Emilia I. Sato13, Vibke Lilleby14, Thomas Fleisher15 and Raphaela Goldbach-Mansky4, 1Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 2Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3NIAMS/NIH, Bethesda, MD, 4Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 5Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, 6Head Immunology Department, Azerbaijan Medical University, Baku, Azerbaijan, 7University of Federal De Sao Paulo, Sao Paulo, Brazil, 8Pediatric Rheumatology, Inova Fairfax Hospital for Children, Fairfax, VA, 9Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 10Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ, 11Pediatric Rheumatology, Children's Specialty Physicians, Omaha, NE, 12Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 13Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 14Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 15Chief Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD

    Background/Purpose The role of IL-1 in the pathogenesis of many of the monogenic autoinflammatory diseases is clinically validated by the response to IL-1 blocking therapies.…
  • Abstract Number: 1897 • 2014 ACR/ARHP Annual Meeting

    Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma

    Kathryn S. Torok1, Katherine Kurzinski2, Christina Kelsey3, Kelsey Magee4, Jonathan Yabes5, Abbe N. Vallejo6, Thomas A. Medsger Jr.7 and Carol A. Feghali-Bostwick8, 1Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA, 4Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, 5Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 6Department of Immunology, University of Pittsburgh, Pittsburgh, PA, 7Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, 8Medicine, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissues which results in disfigurement and orthopedic complications, especially when the onset…
  • Abstract Number: 1880 • 2014 ACR/ARHP Annual Meeting

    Moderate Alcohol Consumption Is Associated with Lower Risk (and severity) of Chronic Widespread Pain: Results from a Population-Based Study

    Gary J. Macfarlane and Marcus Beasley, Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom

    Background/Purpose: Amongst patients with fibromyalgia, alcohol consumption has been reported in a single clinical study to be associated with lower severity of symptoms. This study…
  • Abstract Number: 1879 • 2014 ACR/ARHP Annual Meeting

    The Efficacy of Pregabalin for Treating Fibromyalgia Patients with Moderate or Severe Baseline Widespread Pain

    Andrew Clair and Birol Emir, Pfizer Inc, New York, NY

    Background/Purpose: Pregabalin has demonstrated efficacy for the treatment of fibromyalgia (FM), but insufficient evidence exists on how the efficacy of pregabalin may differ by baseline…
  • Abstract Number: 1878 • 2014 ACR/ARHP Annual Meeting

    A Combination of Celecoxib and Famciclovir Is Efficacious in the Treatment of Fibromyalgia: Results of a Phase IIa Randomized, Double-Blind, Placebo-Controlled Study

    William Pridgen1, Carol Duffy2, Judith Gendreau3 and R Michael Gendreau3, 1Innovative Med Concepts, Tuscaloosa, AL, 2Biological Sciences, University of Alabama, Tuscaloosa, AL, 3Gendreau Consulting, LLC, Poway, CA

    Background/Purpose: Fibromyalgia (FM) is a common chronic pain syndrome with symptoms that include widespread pain, fatigue, sleep disruption and cognitive impairment.  It is known that…
  • Abstract Number: 1877 • 2014 ACR/ARHP Annual Meeting

    Pregnancy Outcomes in SLE: Before and after

    Elizabeth V. Arkema1, Kristin Palmsten2, Christopher Sjöwall3, Elisabet Svenungsson4, Jane E. Salmon5 and Julia F Simard6, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Pediatrics, University of California, San Diego, La Jolla, CA, 3Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, 4Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA

    Background/Purpose: Numerous investigators have demonstrated that the risks of pre-eclampsia, preterm delivery, and fetal death are increased in lupus pregnancies. Adverse events during pregnancy, delivery,…
  • Abstract Number: 1876 • 2014 ACR/ARHP Annual Meeting

    Influence of Alcohol Consumption on the Risk of SLE Among Women in the Nurses’ Health Studies

    Medha Barbhaiya, Bing Lu, Shun-Chiao Chang, Jeffrey A. Sparks, Elizabeth W. Karlson and Karen H. Costenbader, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Prior case-control studies have reported an inverse association between moderate alcohol consumption and the development of SLE. However, case-control studies may be prone to…
  • Abstract Number: 1875 • 2014 ACR/ARHP Annual Meeting

    Can Allopurinol Survival Impact Reverse Depending on Patients’ Characteristics? a Propensity-Score-Based Subgroup Analysis

    Na Lu1, Hyon K. Choi2, Maureen Dubreuil3,4, Qiong Louie-Gao5 and Yuqing Zhang1, 1Boston University School of Medicine, Boston, MA, 2Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Rheumatology, Boston University Medical Center, Boston, MA, 4Rheumatology, Boston VA HealthCare System, Boston, MA, 5Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Several studies have reported that allopurinol use is associated with a decreased risk of death or cardiovascular outcomes. While these studies reported the overall…
  • Abstract Number: 1874 • 2014 ACR/ARHP Annual Meeting

    Obesity Paradox in Recurrent Gout – a Metrological Clarification and Remedy

    Uyen Sa D.T. Nguyen1,2, Qiong Louie-Gao3, Yuqing Zhang4, David T. Felson3, Michael P. Lavalley5 and Hyon K. Choi6, 1Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, 2Clinical Epidemiology Research &Training Unit, Boston University School of Medicine, Boston, MA, 3Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, 4Boston University School of Medicine, Boston, MA, 5Biostatistics, Boston University, Boston, MA, 6Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Obesity is a strong risk factor of incident gout, but previous research showed no such association with recurrent gout among gout patients. These paradoxical…
  • « Previous Page
  • 1
  • …
  • 1924
  • 1925
  • 1926
  • 1927
  • 1928
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology